Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node ...

@article{67341,
   author = {Žatecký, Jan and Coufal, Oldřich and Holánek, Miloš and Kubala, Otakar and Kepičová, Markéta and Gatěk, Jiří and Lerch, Milan and Peteja, Matúš},
   article_number = {1},
   doi = {http://dx.doi.org/10.47717/turkjsurg.2023.5984},
   keywords = {Breast cancer; sentinel lymph node biopsy; neoadjuvant chemotherapy; axillary dissection; level I axillary dissection},
   language = {eng},
   issn = {2564-6850},
   journal = {Turkish Journal of Surgery},
   title = {Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging},
   url = {https://turkjsurg.com/full-text/1889/eng},
   volume = {39},
   year = {2023}
}

TY  - JOUR
ID  - 67341
AU  - Žatecký, Jan - Coufal, Oldřich - Holánek, Miloš - Kubala, Otakar - Kepičová, Markéta - Gatěk, Jiří - Lerch, Milan - Peteja, Matúš
PY  - 2023
TI  - Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging
JF  - Turkish Journal of Surgery
VL  - 39
IS  - 1
SP  - 1-6
EP  - 1-6
SN  - 25646850
KW  - Breast cancer
KW  - sentinel lymph node biopsy
KW  - neoadjuvant chemotherapy
KW  - axillary dissection
KW  - level I axillary dissection
UR  - https://turkjsurg.com/full-text/1889/eng
N2  - Objective: The purpose of the study was to investigate the oncological sufficiency of level I axillary dissection for adequate histological nodal staging (ypN) in patients with breast cancer and tumor-involved sentinel lymph node (SLN) after neoadjuvant chemotherapy (NAC). Material and Methods: A prospective multicentre pilot study took place from 01.01.2018 to 30.11.2020 in three mammary centres in the Czech Republic in patients with breast cancer after NAC (NCT03556397). Patients in the cohort with positive histological frozen section of SLN were indicated to separate axillary dissection of levels I and II. Results: Sixty-one patients with breast cancer after NAC were included in the study according to inclusion and exclusion criteria. Twelve patients with breast cancer and tumour involved SLN after NAC were further included in the analysis. Two (16.7%) patients had positive non-sentinel lymph nodes in level I only, one (8.3%) patient had positive lymph nodes in level II only, and seven (58.3%) patients had positive lymph nodes in both levels. Level I axillary dissection in a patient with tumour involved SLN after NAC would have resulted in understaging in five (41.7%) patients, mostly ypN1 instead of ypN2. Conclusion: According to our pilot result, level I axillary dissection is not sufficient in terms of adequate histological nodal staging in breast cancer patients after NAC, and level II axillary dissection should not be omitted.
ER  - 

ŽATECKÝ, Jan, Oldřich COUFAL, Miloš HOLÁNEK, Otakar KUBALA, Markéta KEPIČOVÁ, Jiří GATĚK, Milan LERCH a Matúš PETEJA. Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging. \textit{Turkish Journal of Surgery}. 2023, roč.~39, č.~1, s.~1-6. ISSN~2564-6850. Dostupné z: https://dx.doi.org/10.47717/turkjsurg.2023.5984.